BGLC - Company ID 0001737523
The table below shows BioNexus Gene Lab Corp's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | $76.16K | $22.84K | $2.54M | $2.26M | $2.14M | $2.63M |
| Cost of revenue | $63.17K | $23.63K | $2.17M | $1.89M | $1.79M | $2.30M |
| Gross profit | $12.98K | -$790.00 | $377.69K | $368.02K | $343.49K | $326.54K |
| R&D | $13.67K | $14.49K | $14.88K | $12.56K | $12.14K | $10.44K |
BioNexus Gene Lab Corp reported annual revenue of $7.42M for fiscal year 2025. That is down 21.9% from $9.51M in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $212.33K (FY 2018) to $7.42M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $298.53K | $327.67K | $445.69K | $516.79K | $391.88K | $792.41K |
| Operating income | -$282.40K | -$540.49K | -$702.51K | -$611.29K | -$618.42K | -$1.34M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.55K |
| Net income | -$286.45K | -$543.58K | -$708.99K | -$616.17K | -$623.33K | -$1.35M |
| EPS (diluted) | -$0.12 | -$0.23 | -$0.40 | -$0.34 | -$0.35 | -$0.75 |